bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figure S7 from Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs
Authors: Stinson Jordan A. , Barbosa Matheus Moreno P. , Sheen Allison , Momin Noor , Fink Elizabeth , Hampel Jordan , Selting Kim A. , Kamerer Rebecca L. , Bailey Keith L. , Wittrup Karl D. , Fan Timothy M.
Published: September 2024

Supplemental Figure S7. IHC analysis of delayed responder shows absence of melanoma.
Supplemental Figure S3 from Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs
Authors: Stinson Jordan A. , Barbosa Matheus Moreno P. , Sheen Allison , Momin Noor , Fink Elizabeth , Hampel Jordan , Selting Kim A. , Kamerer Rebecca L. , Bailey Keith L. , Wittrup Karl D. , Fan Timothy M.
Published: September 2024

Supplemental Figure S3. IL2/IL12 cytokine dose does not appear to correlate with tumor response or survival.
Supplemental Figure S2 from Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs
Authors: Stinson Jordan A. , Barbosa Matheus Moreno P. , Sheen Allison , Momin Noor , Fink Elizabeth , Hampel Jordan , Selting Kim A. , Kamerer Rebecca L. , Bailey Keith L. , Wittrup Karl D. , Fan Timothy M.
Published: September 2024

Supplemental Figure S2. Kaplan-Meier survival plots of dogs treated for malignant melanoma.
Supplementary Figure S10 from Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer
Authors: Karamitopoulou Eva , Wenning Anna S. , Acharjee Animesh , Aeschbacher Pauline , Marinoni Ilaria , Zlobec Inti , Gloor Beat , Perren Aurel
Published: September 2024

Suppl. Figure S10: Immunohistochemical staining and proximity histograms showing that CD8+ Tcells are significantly closer to tumor cells in HI-PDACs than in LI-PDACs
Supplementary Video S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Authors: Stone Logan D. , Kasten Benjamin B. , Rao Shilpa , Gonzalez Manuel. L. , Stevens Todd M. , Lin Diana , Carroll William , Greene Benjamin , Moore Lindsay S. , Fuson Andrew , James Sherin , Hartman Yolanda E. , McCammon Susan , Panuganti Bharat , Nabell Lisle M. , Li Yufeng , Li Mei , Bailey Luke , Rosenthal Eben L. , Jeyarajan Harishanker , Thomas Carissa M. , Warram Jason M.
Published: September 2024

Supplementary Video S2: Locating missed OPSCC fragment using intraoperative robot fluorescence.
Supplementary Table S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Authors: Stone Logan D. , Kasten Benjamin B. , Rao Shilpa , Gonzalez Manuel. L. , Stevens Todd M. , Lin Diana , Carroll William , Greene Benjamin , Moore Lindsay S. , Fuson Andrew , James Sherin , Hartman Yolanda E. , McCammon Susan , Panuganti Bharat , Nabell Lisle M. , Li Yufeng , Li Mei , Bailey Luke , Rosenthal Eben L. , Jeyarajan Harishanker , Thomas Carissa M. , Warram Jason M.
Published: September 2024

Supplementary Table S3: Representativeness of Study Participants.
Figure S1 from Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
Authors: Iida Naoko , Imai Mitsuho , Okamoto Wataru , Kato Takeshi , Esaki Taito , Kato Ken , Komatsu Yoshito , Yuki Satoshi , Masuishi Toshiki , Nishina Tomohiro , Ebi Hiromichi , Taniguchi Hiroya , Nonomura Norio , Sunakawa Yu , Shiozawa Manabu , Yamazaki Kentaro , Boku Shogen , Bando Hideaki , Shiraishi Yuichi , Kobayashi Maki , Goto Hiroki , Sato Akihiro , Fujii Satoshi , Yoshino Takayuki , Nakamura Yoshiaki
Published: September 2024

Figure S1
Supplementary Table S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Authors: Stone Logan D. , Kasten Benjamin B. , Rao Shilpa , Gonzalez Manuel. L. , Stevens Todd M. , Lin Diana , Carroll William , Greene Benjamin , Moore Lindsay S. , Fuson Andrew , James Sherin , Hartman Yolanda E. , McCammon Susan , Panuganti Bharat , Nabell Lisle M. , Li Yufeng , Li Mei , Bailey Luke , Rosenthal Eben L. , Jeyarajan Harishanker , Thomas Carissa M. , Warram Jason M.
Published: September 2024

Supplementary Table S1: Patient demographics.
Supplementary Figure S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Authors: Stone Logan D. , Kasten Benjamin B. , Rao Shilpa , Gonzalez Manuel. L. , Stevens Todd M. , Lin Diana , Carroll William , Greene Benjamin , Moore Lindsay S. , Fuson Andrew , James Sherin , Hartman Yolanda E. , McCammon Susan , Panuganti Bharat , Nabell Lisle M. , Li Yufeng , Li Mei , Bailey Luke , Rosenthal Eben L. , Jeyarajan Harishanker , Thomas Carissa M. , Warram Jason M.
Published: September 2024

Supplementary Figure S3: Additional characterization of consecutive OPSCC presentations in a single patient.
Figure S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
Authors: Grazini Ursula , Markovets Aleksandra , Ireland Lucy , O’Neill Daniel , Phillips Benjamin , Xu Man , Pfeifer Matthias , Vaclova Tereza , Martin Matthew J. , Bigot Ludovic , Friboulet Luc , Hartmaier Ryan , Cuomo Maria E. , Barry Simon T. , Smith Paul D. , Floc’h Nicolas
Published: September 2024

Figure S1: AURA3 with pre-existing alterations in PTEN/PIK3CA-osimertinib arm.
Supplementary Table S2 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Authors: Yang Yazi , Qin Sen , Yang Mengyu , Wang Ting , Feng Ru , Zhang Chunli , Zheng Enrun , Li Qinghua , Xiang Pengyu , Ning Shangyong , Xu Xiaodong , Zuo Xin , Zhang Shuai , Yun Xiaoya , Zhou Xuehong , Wang Yue , He Lin , Shang Yongfeng , Sun Luyang , Liu Hui
Published: September 2024

Supplementary Table S2. Clinical Assessment of MM Patients after BCMA CAR-T Therapy.
Supplementary Table S5 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Authors: Sweeney Christopher J. , Petry Russell , Xu Chang , Childress Merrida , He Jie , Fabrizio David , Gjoerup Ole , Morley Samantha , Catlett Timothy , Assaf Zoe J. , Yuen Kobe , Wongchenko Matthew , Shah Kalpit , Gupta Pratyush , Hegde Priti , Pasquina Lincoln W. , Mariathasan Sanjeev , Graf Ryon P. , Powles Thomas
Published: September 2024

Overall response rate and landmark outcomes by ctDNA TF and PSA reduction
Supplementary Figure S7 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Authors: Yang Yazi , Qin Sen , Yang Mengyu , Wang Ting , Feng Ru , Zhang Chunli , Zheng Enrun , Li Qinghua , Xiang Pengyu , Ning Shangyong , Xu Xiaodong , Zuo Xin , Zhang Shuai , Yun Xiaoya , Zhou Xuehong , Wang Yue , He Lin , Shang Yongfeng , Sun Luyang , Liu Hui
Published: September 2024

Supplementary Figure S7. BCMA CAR-T Therapy Attenuates BAFF/GALECTIN/MK Pathway-mediated Immunosuppression and Activates MIF Pathway-mediated Anti-MM Immunity.
Supplementary Figure S3 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Authors: Yang Yazi , Qin Sen , Yang Mengyu , Wang Ting , Feng Ru , Zhang Chunli , Zheng Enrun , Li Qinghua , Xiang Pengyu , Ning Shangyong , Xu Xiaodong , Zuo Xin , Zhang Shuai , Yun Xiaoya , Zhou Xuehong , Wang Yue , He Lin , Shang Yongfeng , Sun Luyang , Liu Hui
Published: September 2024

Supplementary Figure S3. Cytogenetic Abnormality-associated Gene Expression and Clonal Evolution in MM Cells.
Supplementary Figure S10 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Authors: Sweeney Christopher J. , Petry Russell , Xu Chang , Childress Merrida , He Jie , Fabrizio David , Gjoerup Ole , Morley Samantha , Catlett Timothy , Assaf Zoe J. , Yuen Kobe , Wongchenko Matthew , Shah Kalpit , Gupta Pratyush , Hegde Priti , Pasquina Lincoln W. , Mariathasan Sanjeev , Graf Ryon P. , Powles Thomas
Published: September 2024

Prognostic value of on-treatment ctDNA TF detection and 90% PSA reduction
Supplementary Figure S1 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Authors: Sweeney Christopher J. , Petry Russell , Xu Chang , Childress Merrida , He Jie , Fabrizio David , Gjoerup Ole , Morley Samantha , Catlett Timothy , Assaf Zoe J. , Yuen Kobe , Wongchenko Matthew , Shah Kalpit , Gupta Pratyush , Hegde Priti , Pasquina Lincoln W. , Mariathasan Sanjeev , Graf Ryon P. , Powles Thomas
Published: September 2024

CONSORT diagram
Supplementary Table S1 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Authors: Grewal Eric P. , Richardson Leland G.K. , Sun Jing , Ramapriyan Rishab , Martinez-Lage Maria , Miller Julie J. , Carter Bob S. , Cahill Daniel P. , Curry William T. , Choi Bryan D.
Published: September 2024

Supplementary Table 1. Clinical characteristics of glioma patients and samples
Supplementary Table S4 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
Authors: Tobias Joshua , Maglakelidze Marina , Andrić Zoran , Ryspayeva Dinara , Bulat Iurie , Nikolić Ivan , Petrović Zoran , Chawla Tanuj , Nagarkar Rajnish , Garner-Spitzer Erika , Zielinski Christoph C. , Chong Leslie Mi Ok , Nixon Bonnie , Ede Nicholas J. , Yavrom Sharon , Kundi Michael , Wiedermann Ursula
Published: September 2024

Supplementary Table S4. Overall response rates (by BICR).
Supplementary Table S2 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
Authors: Tobias Joshua , Maglakelidze Marina , Andrić Zoran , Ryspayeva Dinara , Bulat Iurie , Nikolić Ivan , Petrović Zoran , Chawla Tanuj , Nagarkar Rajnish , Garner-Spitzer Erika , Zielinski Christoph C. , Chong Leslie Mi Ok , Nixon Bonnie , Ede Nicholas J. , Yavrom Sharon , Kundi Michael , Wiedermann Ursula
Published: September 2024

Supplementary Table S2. Representativeness of Study Participants.
Supplementary Materials and Methods S1 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
Authors: Tobias Joshua , Maglakelidze Marina , Andrić Zoran , Ryspayeva Dinara , Bulat Iurie , Nikolić Ivan , Petrović Zoran , Chawla Tanuj , Nagarkar Rajnish , Garner-Spitzer Erika , Zielinski Christoph C. , Chong Leslie Mi Ok , Nixon Bonnie , Ede Nicholas J. , Yavrom Sharon , Kundi Michael , Wiedermann Ursula
Published: September 2024

Supplementary Materials and Methods
Supplementary Table 3 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Supplementary Table 3. Expanded clinicopathological parameters and preclinical models established from PMP patients enrolled in the study.
Supplementary Table 2 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Supplementary Table 2. Primer sets of target genes.
Supplementary Figure S5 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
Authors: Tobias Joshua , Maglakelidze Marina , Andrić Zoran , Ryspayeva Dinara , Bulat Iurie , Nikolić Ivan , Petrović Zoran , Chawla Tanuj , Nagarkar Rajnish , Garner-Spitzer Erika , Zielinski Christoph C. , Chong Leslie Mi Ok , Nixon Bonnie , Ede Nicholas J. , Yavrom Sharon , Kundi Michael , Wiedermann Ursula
Published: September 2024

Supplementary Figure S5. Levels of total IgG antibodies and IgG isotypes in the patients treated with chemotherapy alone or HER-Vaxx plus chemotherapy.
Supplementary Figure S3 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
Authors: Tobias Joshua , Maglakelidze Marina , Andrić Zoran , Ryspayeva Dinara , Bulat Iurie , Nikolić Ivan , Petrović Zoran , Chawla Tanuj , Nagarkar Rajnish , Garner-Spitzer Erika , Zielinski Christoph C. , Chong Leslie Mi Ok , Nixon Bonnie , Ede Nicholas J. , Yavrom Sharon , Kundi Michael , Wiedermann Ursula
Published: September 2024

Supplementary Figure S3. The Kaplan-Meier estimate of OS.
Supplementary Figure S2 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
Authors: Tobias Joshua , Maglakelidze Marina , Andrić Zoran , Ryspayeva Dinara , Bulat Iurie , Nikolić Ivan , Petrović Zoran , Chawla Tanuj , Nagarkar Rajnish , Garner-Spitzer Erika , Zielinski Christoph C. , Chong Leslie Mi Ok , Nixon Bonnie , Ede Nicholas J. , Yavrom Sharon , Kundi Michael , Wiedermann Ursula
Published: September 2024

Supplementary Figure S2. Adverse Events (AEs), with grade 1/2 or ≥3 associated with the respective treatments in the study arms.
Supplementary Figure 5 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Supplementary Figure 5. Treatment with BRAF inhibitor is enough to prolong RAS/ERK signaling pathway blockage in PMP models.
Supplementary Figure 1 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Supplementary Figure 1. PMP preclinical organoid models preserve histological markers and chemotherapy resistance from the original patient sample and present different patterns of mucinous secretion.
Figure 1 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Generation of a collection of PMP-PDO, PDX, and PDXO models. A, Design showing the generation of PDO from tumor tissues of patients with PMP. B, Pictures of PMP-PDO models after 7 days in culture (PMP18.3, left image and PMP21.5, right image). Scale bar, 500 μm. C, Expansion of PMP-PDO models after dissociation with TrypLE Express reagent at day 2 (left) and day 7 (right; PMP5.2). Scale bar, 500 μm D, Design showing the generation of PDX and PDXO from tumor tissues of patients with PMP. PM, Peritoneal metastases. E–G, Macroscopic images from an orthotopic PMP-PDX (oPDX) models in mice derived from low-grade G1 (E and F; PMP3.1) or high-grade G3 (G; PMP5.1) samples from patients with mucinous carcinoma peritonei. Tumor mass is indicated by red arrows. H and I, H&E staining from low-grade G1 (H; PMP3.1) and high-grade G3 (I; PMP5.1) samples from patients with mucinous carcinoma peritonei and associated oPDXs. Scale bar, 2.5 mm and 100 μm. J, H&E staining from a subcutaneous PMP-PDX (sPDX) model derived from the sample from patient with high-grade G3 mucinous carcinoma peritonei (PMP5.1). Scale bar, 2.5 mm and 100 μm. (A and D, Created with BioRender.com.). PMP, Pseudomyxoma peritonei.
Data from Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade
Authors: Jeon Seung Hyuck , You Gihoon , Park Junsik , Chung Youseung , Park Kyungjin , Kim Hyunjoo , Jeon Jaehyoung , Kim Youngkwang , Son Woo-Chan , Jeong Da Som , Shin Eui-Cheol , Lee Jung-Yun , Han Dai Hoon , Jung Jaeho , Park Su-Hyung
Published: September 2024

AbstractPurpose:
To overcome the limited efficacy of immune checkpoint blockade, there is a need to find novel cancer immunotherapeutic strategies for the optimal treatment of cancer. The novel anti–4-1BB×PDL1 bispecific antibody—ABL503 (also known as TJ-L14B)—was designed to simultaneously target PDL1 and 4-1BB and demonstrated strong antitumor T-cell responses without considerable toxicity. In this study, we investigated the mechanisms by which the combination of ABL503 and anti-PD1 blockade affected the reinvigoration of exhausted tumor-infiltrating CD8+ T cells (CD8+ TIL) and antitumor efficacy.
Experimental Design:
Single-cell suspensions of hepatocellular carcinoma and ovarian cancer tissues from treatment-naïve patients were used for immunophenotyping of CD8+ TILs and in vitro functional assays. Humanized hPD1/hPDL1/h4-1BB triple–knock-in mice were used to evaluate the effects of ABL503 and anti-PD1 blockade in vivo.
Results:
We observed that ABL503 successfully restored the functions of 4-1BB+ exhausted CD8+ TILs, which were enriched for tumor-specific T cells but unresponsive to anti-PD1 blockade. Importantly, compared with anti-PD1 blockade alone, the combination of ABL503 and anti-PD1 blockade further enhanced the functional restoration of human CD8+ TILs in vitro. Consistently, the combination of ABL503 with anti-PD1 in vivo significantly alleviated tumor growth and induced enhanced infiltration and activation of CD8+ TILs.
Conclusions:
ABL503, a PDL1 and 4-1BB dual-targeting bispecific antibody, elicits pronounced additive tumor growth inhibition, with increased infiltration and functionality of exhausted CD8+ T cells, which in turn enhances the anticancer effects of anti-PD1 blockade. These promising findings suggest that ABL503 (TJ-L14B) in combination with PD1 inhibitors will likely further enhance therapeutic benefit in clinical trials.

See related commentary by Molero-Glez et al., p. 3971
Data from Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment
Authors: Chelushkin Maksim A. , van Dorp Jeroen , van Wilpe Sandra , Seignette Iris M. , Mellema Jan-Jaap J. , Alkemade Maartje , Gil-Jimenez Alberto , Peters Dennis , Brugman Wim , Stockem Chantal F. , Hooijberg Erik , Broeks Annegien , van Rhijn Bas W.G. , Mertens Laura S. , van der Heijden Antoine G. , Mehra Niven , van Montfoort Maurits L. , Wessels Lodewyk F.A. , Vis Daniel J. , van der Heijden Michiel S.
Published: September 2024

AbstractPurpose:
Platinum-based chemotherapy and immune checkpoint inhibitors are key components of systemic treatment for muscle-invasive and advanced urothelial cancer. The ideal integration of these two treatment modalities remains unclear as clinical trials have led to inconsistent results. Modulation of the tumor-immune microenvironment by chemotherapy is poorly characterized. We aimed to investigate this modulation, focusing on potential clinical implications for immune checkpoint inhibitor response.
Experimental Design:
We assessed immune cell densities, spatial relations, and tumor/stromal components from 116 patients with urothelial bladder cancer (paired data for 95 patients) before and after platinum-based chemotherapy.
Results:
Several published biomarkers for immunotherapy response changed upon chemotherapy treatment. The intratumoral CD8+ T-cell percentage increased after treatment and was associated with increased TNFα-via-NF-κB signaling. The percentage of PDL1+ immune cells was higher after chemotherapy. An increase in chemo-induced changes that potentially inhibit an antitumor immune response was also observed, including increased fibroblast-based TGFβ signaling and distances from immune cells to the nearest cancer cell. The latter two parameters correlated significantly in posttreatment samples, suggesting that TGFβ signaling in fibroblasts may play a role in spatially separating immune cells from cancer cells. We examined specific chemotherapy regimens and found that treatment with methotrexate, vinblastine, doxorubicin, and cisplatin was associated with an increase in the macrophage cell percentage. Gemcitabine-containing chemotherapy was associated with upregulation of fibroblast TGFβ signaling.
Conclusions:
The opposing effects of platinum-based chemotherapy on the immune cell composition and stromal context of the tumor-immune microenvironment may explain the inconsistent results of clinical trials investigating chemotherapy and immune checkpoint inhibitor combinations in bladder cancer.
Data from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Authors: Yang Yazi , Qin Sen , Yang Mengyu , Wang Ting , Feng Ru , Zhang Chunli , Zheng Enrun , Li Qinghua , Xiang Pengyu , Ning Shangyong , Xu Xiaodong , Zuo Xin , Zhang Shuai , Yun Xiaoya , Zhou Xuehong , Wang Yue , He Lin , Shang Yongfeng , Sun Luyang , Liu Hui
Published: September 2024

AbstractPurpose:
The purpose of this study was to investigate the remodeling of the multiple myeloma microenvironment after B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T (CAR-T) cell therapy.
Experimental Design:
We performed single-cell RNA sequencing on paired bone marrow specimens (n = 14) from seven patients with multiple myeloma before (i.e., baseline, “day −4”) and after (i.e., “day 28”) lymphodepleted BCMA CAR-T cell therapy.
Results:
Our analysis revealed heterogeneity in gene expression profiles among multiple myeloma cells, even those harboring the same cytogenetic abnormalities. The best overall responses of patients over the 15-month follow-up are positively correlated with the abundance and targeted cytotoxic activity of CD8+ effector CAR-T cells on day 28 after CAR-T cell infusion. Additionally, favorable responses are associated with attenuated immunosuppression mediated by regulatory T cells, enhanced CD8+ effector T-cell cytotoxic activity, and elevated type 1 conventional dendritic cell (DC) antigen presentation ability. DC re-clustering inferred intramedullary-originated type 3 conventional DCs with extramedullary migration. Cell–cell communication network analysis indicated that BCMA CAR-T therapy mitigates BAFF/GALECTIN/MK pathway–mediated immunosuppression and activates MIF pathway–mediated anti–multiple myeloma immunity.
Conclusions:
Our study sheds light on multiple myeloma microenvironment dynamics after BCMA CAR-T therapy, offering clues for predicting treatment responsivity.
Data from Cryoablation Does Not Significantly Contribute to Systemic Effector Immune Responses in a Poorly Immunogenic B16F10 Melanoma Model
Authors: Yakkala Chakradhar , Corria-Osorio Jesus , Kandalaft Lana , Denys Alban , Koppolu Bhanu , Duran Rafael
Published: September 2024

AbstractPurpose:
Cryoablation is a minimally invasive procedure implemented to destroy solid tumors. It also results in the release of tumor antigens into the systemic circulation. Preclinical studies using immunogenic tumor models have shown that cryoablation evokes antitumor immune responses. The mechanisms by which cryoablation impacts immune responses in poorly immunogenic tumors have not been sufficiently explored.
Experimental Design:
We used a bilateral B16F10 melanoma model devoid of strong immunogenic antigens. Cryoablation-induced effector immune responses were investigated, also in combination with a peritumoral STING agonist and systemic anti–PD-1. Selective immune cell depletion, T-cell migration arrest, in vivo T-cell transplantation, and cryoablation versus surgical removal techniques were used to determine the contribution of cryoablation and immunotherapies to systemic antitumor effector immune responses.
Results:
Treatment of a tumor with cryoablation + STING agonist + anti–PD-1 resulted in the rejection of unablated, contralateral tumors. Depletion studies demonstrated that tumor rejection is essentially dependent on CD8+ T cells. T-cell arrest in the lymph nodes had no effect on the rejection process. Splenic CD8+ T cells isolated from cryoablation-treated mice with B16F10 melanoma, upon transplantation into melanoma-bearing recipients, did not impact the recipient’s tumor growth. Finally, comparison of cryoablation + STING agonist + anti–PD-1 versus surgery + STING agonist + anti–PD-1 in the bilateral tumor model showed no difference in the rejection of contralateral tumors.
Conclusions:
Cryoablation does not significantly contribute to systemic antitumor effector immune responses in a B16F10 melanoma model. Cryoablation primarily performs tumor debulking, and immunotherapy functions independently of cryoablation in eliciting antitumor effector immune responses.
Data from CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma
Authors: Pobbati Ajaybabu V. , Burtscher Ashley , Rajaram Siva Nandini , Hallett Andrea , Romigh Todd , Che Kepeng , Zhao Bin , Coker Jesse A. , Wang Nancy , Stauffer Shaun R. , Rubin Brian P.
Published: September 2024

AbstractPurpose:
There are no effective treatment options for patients with aggressive epithelioid hemangioendothelioma (EHE) driven by the TAZ–CAMTA1 (TC) fusion gene. Here, we aimed to understand the regulation of TC using pharmacologic tools and identify vulnerabilities that can potentially be exploited for the treatment of EHE.
Experimental Design:
TC is a transcriptional coregulator; we hypothesized that compounds that reduce TC nuclear levels, either through translocation of TC to the cytoplasm, or through degradation, would render TC less oncogenic. TC localization was monitored using immunofluorescence in an EHE tumor cell line. Two target-selective libraries were used to identify small molecules that reduce TC localization in the nucleus. The ability of the shortlisted hits to affect cell viability, apoptosis, and tumorigenesis was also evaluated.
Results:
Basal TC remained “immobile” in the nucleus; administration of cyclin-dependent kinase (CDK) inhibitors such as CGP60474 and dinaciclib (Dina) mobilized TC. “Mobile” TC shuttled between the nucleus and cytoplasm; however, it was eventually degraded through proteasomes. This dramatically suppressed the levels of TC-regulated transcripts and cell viability, promoted apoptosis, and reduced the area of metastatic lesions in the allograft model of EHE. We specifically identified that the inhibition of CDK9, a transcriptional CDK, destabilizes TC.
Conclusions:
The CDK inhibitor Dina exhibited antitumorigenic properties both in vitro and in vivo in EHE models. Dina has been rigorously tested in clinical trials and displayed an acceptable toxicity profile. Therefore, there is a potential therapeutic window for repurposing Dina for the treatment of EHE.
Data from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Authors: Grewal Eric P. , Richardson Leland G.K. , Sun Jing , Ramapriyan Rishab , Martinez-Lage Maria , Miller Julie J. , Carter Bob S. , Cahill Daniel P. , Curry William T. , Choi Bryan D.
Published: September 2024

AbstractPurpose:
Mutations in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 have critical diagnostic and prognostic significance in diffuse gliomas. Neomorphic mutant IDH activity has been previously implicated in T-cell suppression; however, the effects of IDH mutations on intratumoral myeloid populations remain underexplored. In this study, we investigate the influence of IDH status on the myeloid compartment using human glioma specimens and preclinical models.
Experimental Design:
We performed RNA sequencing and quantitative immunofluorescence on newly diagnosed, treatment-naive IDH-mutant grade 4 astrocytoma and IDH-wild-type (IDH-WT) glioblastoma (GBM) specimens. We also generated a syngeneic murine model, comparing transcriptomic and cell-level changes in paired isogenic glioma lines that differ only in IDH mutational status.
Results:
Among patient samples, IDH-mutant tumors displayed an underrepresentation of suppressive myeloid transcriptional signatures, which was confirmed at the cellular level with decreased numbers of intratumoral M2-like macrophages and myeloid-derived suppressor cells. Introduction of the mutant IDH enzyme into murine glioma was sufficient to recapitulate the transcriptomic and cellular shifts observed in patient samples.
Conclusions:
We provide transcriptomic and cellular evidence that mutant IDH is associated with a quantitative reduction of suppressive myeloid cells in gliomas and that introduction of the mutant enzyme is sufficient to result in corresponding cellular changes using an in vivo preclinical model. These data advance our understanding of high-grade gliomas by identifying key myeloid cell populations that are reprogrammed by mutant IDH and may be targetable through therapeutic approaches.
Data from A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma
Authors: Grommes Christian , Nandakumar Subhiksha , Schaff Lauren R. , Gavrilovic Igor , Kaley Thomas J. , Nolan Craig P. , Stone Jacqueline , Thomas Alissa A. , Tang Sarah S. , Wolfe Julia , Bozza Alexis , Wongchai Venissala , Hyde Alisson , Barrett Emma , Lynch Elizabeth A. , Madzsar Juli T. , Lin Andrew , Piotrowski Anna F. , Pentsova Elena , Francis Jasmine H. , Hatzoglou Vaios , Schultz Nikolaus , Reiner Anne S. , Panageas Katherine S. , DeAngelis Lisa M. , Mellinghoff Ingo K.
Published: September 2024

AbstractPurpose:
Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase. We previously reported the safety and short-term antitumor activity of ibrutinib in 20 patients with relapsed or refractory (r/r) primary central nervous system (CNS) lymphoma (PCNSL) or secondary CNS lymphoma (SCNSL).
Patients and Methods:
We enrolled 26 additional patients with r/r PCNSL/SCNSL into the dose-expansion cohort of the trial into a combined cohort of 46 patients (31 with PCNSL and 15 with SCNSL). Patients received ibrutinib at 560 or 840 mg daily in the dose-escalation cohort and ibrutinib at 840 mg daily in the expansion cohort. The median follow-up was 49.9 and 62.1 months for patients with PCNSL and SCNSL, respectively. We sequenced DNA from available tumor biopsies and cerebrospinal fluid collected before and during ibrutinib therapy.
Results:
Tumor responses were observed in 23/31 (74%) patients with PCNSL and 9/15 (60%) patients with SCNSL, including 12 complete responses in PCNSL and 7 in SCNSL. The median progression-free survival (PFS) for PCNSL was 4.5 months [95% confidence interval (CI), 2.8–9.2] with 1-year PFS at 23.7% (95% CI, 12.4%–45.1%). The median duration of response in the 23 PCNSL responders was 5.5 months. The median PFS in SCNSL was 5.3 months (95% CI, 1.3–14.5) with a median duration of response of 8.7 months for the 9 responders. Exploratory biomarker analysis suggests that mutations in TBL1XR1 may be associated with a long-term response to ibrutinib in PCNSL (P = 0.0075). Clearance of ctDNA from cerebrospinal fluid was associated with complete and long-term ibrutinib responses.
Conclusions:
Our study confirms single-agent activity of ibrutinib in r/r CNS lymphoma and identifies molecular determinants of response based on long-term follow-up.
MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
Authors: Miranda-Román Miguel A. , Lee Cindy J. , Fishinevich Eve , Ran Leili , Patel Amish J. , Yan Juan , Khudoynazarova Makhzuna N. , Warda Sarah , Pachai Mohini R. , Chen Yu , Chi Ping
Published: September 2024

Purpose:

Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive subtype of soft-tissue sarcoma with a high propensity to metastasize and extremely limited treatment options. Loss of the RAS-GAP NF1 leads to sustained RAF/MEK/ERK signaling in MPNST. However, single-agent MEK inhibitors (MEKi) have failed to elicit a sustained inhibition of the MAPK signaling pathway in MPNST.

Experimental Design:

We used pharmacological, biochemical, and genetic perturbations of the receptor tyrosine kinase and MAPK signaling pathway regulators to investigate the mechanisms of MEKi resistance and evaluated combination therapeutic strategies in various preclinical MPNST models in vitro and in vivo.

Results:

Here, we report that MEKi treatment resistance in MPNST involves two adaptive pathways: direct transcriptional upregulation of the receptor tyrosine kinase PDGFRβ and MEKi-induced increase in RAF dimer formation and activation of downstream signaling. Although the pharmacologic combination of a MEKi with a PDGFRβ-specific inhibitor was more effective than treatment with the MEKi alone, the combination of the MEKi and RAF dimer inhibitors led to a robust inhibition of MAPK pathway signaling. This combination treatment was effective in vitro and in vivo, as demonstrated by the significant increase in drug synergism and its high effectiveness in decreasing MPNST viability.

Conclusions:

Our findings suggest that the combination of MEKis and PDGFR and/or RAF dimer inhibitors can overcome MEKi resistance and may serve as a novel targeted therapeutic strategy for patients with NF1-deficient MPNST, which in turn could impact future clinical investigations for this patient population.
Figure S7 from Putrescine Supplementation Limits the Expansion of pks+ Escherichia coli and Tumor Development in the Colon
Authors: Oliero Manon , Cuisiniere Thibault , Ajayi Ayodeji S. , Gerkins Claire , Hajjar Roy , Fragoso Gabriela , Calvé Annie , Vennin Rendos Hervé , Mathieu-Denoncourt Annabelle , Dagbert François , De Broux Éric , Loungnarath Rasmy , Schwenter Frank , Sebajang Herawaty , Ratelle Richard , Wassef Ramses , Richard Carole , Duperthuy Marylise , Gravel Andrée E. , Vincent Antony T. , Santos Manuela M.
Published: September 2024

Figure S7. Putrescine lowers inflammation, inhibits pks+ E. coli growth, and reduces tumor development.
Figure S2 from Putrescine Supplementation Limits the Expansion of pks+ Escherichia coli and Tumor Development in the Colon
Authors: Oliero Manon , Cuisiniere Thibault , Ajayi Ayodeji S. , Gerkins Claire , Hajjar Roy , Fragoso Gabriela , Calvé Annie , Vennin Rendos Hervé , Mathieu-Denoncourt Annabelle , Dagbert François , De Broux Éric , Loungnarath Rasmy , Schwenter Frank , Sebajang Herawaty , Ratelle Richard , Wassef Ramses , Richard Carole , Duperthuy Marylise , Gravel Andrée E. , Vincent Antony T. , Santos Manuela M.
Published: September 2024

Figure S2 shows the effects of putrescine supplementation on cell proliferation
Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Authors: Gonzalez-Kozlova Edgar , Huang Hsin-Hui , Jagede Opeyemi A. , Tuballes Kevin , Del Valle Diane M. , Kelly Geoffrey , Patel Manishkumar , Xie Hui , Harris Jocelyn , Argueta Kimberly , Nie Kai , Barcessat Vanessa , Moravec Radim , Altreuter Jennifer , Duose Dzifa Y. , Kahl Brad S. , Ansell Stephen M. , Yu Joyce , Cerami Ethan , Lindsay James R. , Wistuba Ignacio I. , Kim-Schulze Seunghee , Diefenbach Catherine S. , Gnjatic Sacha
Published: September 2024

Supplemental Figure 3. Graphical abstract. Top boxes show a simplified trial design including 3 treatments composed by the combination of BV with I, N and I+N. We investigated the differences between responders and non-responders using standardized assays through the CIMAC’s network (ELISA, Olink, CYTOF and TCRseq). Bottom boxes summarize the main findings associated with specific treatments and treatment associated response or resistance.
Supplementary Table 6 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Authors: Mahmood Umair , Blake Andrew , Rathee Sanjay , Samuel Leslie , Murray Graeme , Sebag-Montefiore David , Gollins Simon , West Nicholas P. , Begum Rubina , Bach Simon P. , Richman Susan D. , Quirke Phil , Redmond Keara L. , Salto-Tellez Manuel , Koelzer Viktor H. , Leedham Simon J. , Tomlinson Ian , Dunne Philip D. , Buffa Francesca M. , Maughan Tim S. , Domingo Enric
Published: September 2024

Supplementary Table 6
Supplementary Table 5 from Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures
Authors: Mahmood Umair , Blake Andrew , Rathee Sanjay , Samuel Leslie , Murray Graeme , Sebag-Montefiore David , Gollins Simon , West Nicholas P. , Begum Rubina , Bach Simon P. , Richman Susan D. , Quirke Phil , Redmond Keara L. , Salto-Tellez Manuel , Koelzer Viktor H. , Leedham Simon J. , Tomlinson Ian , Dunne Philip D. , Buffa Francesca M. , Maughan Tim S. , Domingo Enric
Published: September 2024

Supplementary Table 5
A meta-analysis of long-term COVID-19 symptoms
Authors: Prantilla Shi D. , Demayo Cesar G. , Torres Mark Anthony J. , Llantos Orven E.
Published: September 2024

This meta–analysis examines the far–reaching effects of long COVID (LC), highlighting the need for welfare strategies emphasizing the Parity of Esteem. The analysis of clinical studies reveals the prevalence of LC across various demographic factors, including age, gender, infection type, and severity. The findings highlight persistent pulmonary impairments that result in post-COVID pulmonary fibrosis (PCPF), long-term cardiovascular symptoms, gastrointestinal issues, dermatological concerns, and neuropsychiatric outcomes. These effects continue beyond the acute phase of COVID-19, affecting both symptomatic and asymptomatic people. The study emphasizes that LC is not only a physical ailment but also has a significant impact on mental health, necessitating a holistic approach to healthcare. Psychological and emotional distress among LC patients necessitates empathetic support. This study concludes by emphasizing the significance of LC and advocating for data-driven healthcare policies and assistance programs to address the unique challenges encountered by COVID-19 survivors. For managing the long-term effects of LC on both physical and mental health, an unwavering commitment to parity of esteem is crucial.
Low zinc serum affects insulin-like growth factor-1 level in dehydrated pregnant women
Authors: Mulyani Erry Yudhya , Hardinsyah Hardinsyah , Briawan Dodik , Santoso Budi Iman , Jus'at Idrus
Published: September 2024

Maternal body fluids imbalance affects amniotic fluid, serum sodium-potassium, edema, and preeclampsia. Insulin-like growth factor-1 (IGF-1) is a growth hormone and a regulator in sodium balance regulation. This study aimed to determine the correlation of IGF-1, zinc, calcium, and sodium with hydration status and the nutrients impact to IGF-1 based on hydration status of pregnant women at Kebon Jeruk Health-Center, West Jakarta. This cohort-prospective study was conducted in December 2016 to January 2018. A total of 66 pregnant women in the second trimester were examined. Urine color, urine specific gravity, serum sodium, serum osmolality and urine were used as hydration status indicators. Zn, Ca, Na, and IGF-1 levels as the growth indicator from mother to fetus. Pearson correlation test, independent t-test and linear regression were used in statistical analysis. There were no differences in IGF-1, Zn, Ca, and Na serum between the two groups (p³0.05). There was no relationship between Ca, Na and IGF-1 level (p³0.05). The regression results show a possitive relation that low zinc serum affect IGF-1 level in dehydrated pregnant women. Therefore, it is necessary for pregnant women to consume zinc-rich foods to increase IGF-1 level and keep hydration status with water consume 3.0 L per-day.
Teen caregivers living with schizophrenic fathers in West Java
Authors: Bakti Sarah Kusumah , Agustina Hana Rizmadewi , Sriati Aat , Suryani Suryani , Shivji Noureen Asif
Published: September 2024

Adolescents with fathers who have schizophrenia are more likely to experience emotional dysregulation, negative decisions, a failure to form an identity, inconsistency in decision-making, and failure to adapt. This study is aimed to investigate the lived experiences of adolescents who live with a father who has schizophrenia in an urban area of Bandung City, West Java. The qualitative phenomenological approach was used in this study. In-depth interviews were conducted with six adolescent participants, aged 13 to 22, who live in Bandung City with a father diagnosed with schizophrenia. The Colaizzi method was then used to analyze the interview transcripts. Data analysis produced eight major themes: i) dealing with psychosocial problems and moral dilemmas, ii) a lack of closeness between father and children, iii) exposures to violence inside and outside the home, iv) getting the wisdom behind the catastrophe, v) changing roles and responsibilities, vi) a lack of social support, vii) difficulties to share personal issues, and viii) seeking to build a better future. The adolescents still have opportunities to continue building a better future. Improving health promotion and education programs to manage negative emotions and developing Self-Help Groups for adolescents whose fathers have schizophrenia is thus necessary.
Challenges in implementing dengue surveillance in Bantul District Special Region of Yogyakarta, Indonesia
Authors: Astuti Fardhiasih Dwi , Widyaningsih Vitri , Pamungkasari Eti Poncorini , Subijanto Achmad Arman
Published: September 2024

The surveillance system is a source of information for policymaker to address the dengue outbreak. However, there was a lack of information on the effectiveness of dengue surveillance system in reporting the outbreak. This study aims to assess dengue surveillance activities in Bantul District, Special Region of Yogyakarta, Indonesia, one of the districts with a high burden of dengue, to provide information on current effectiveness and need assessment for further improvement for dengue surveillance system. This qualitative study was conducted in Bantul District, Special Region of Yogyakarta. The assessment approach was based on the input-processoutput-outcome (IPOO) model. The study participants were selected based on purposive sampling. Data were collected through interviews. Eight program holder surveillance were interviewed based on the interview guide. The surveillance system in Bantul Regency already utilizes electronic reporting. Reporting cases of dengue uses the system for surveillance of outbreak events (SISKLB). Analysis and interpretation are done to monitor progress in cases. The follow-up evaluation ceses is vector control to prevent the spread of the case. The incidence of dengue is still higher than the national rate. The case fatality rate (CFR) for dengue is <1%; CFR has hit its target. The larvae-free rate hasn't reached its target yet. Optimizing electronic reporting can improve the quality of information used as a reference in decision-making. SISKLB was created for timely reporting and monitoring of dengue cases. Monitoring available data laboratory can be used as a quick response to take action to prevent an increase in cases.
Spirituality and self-management in coronary heart diseases patient
Authors: Fikriana Riza , Afik Al , Aditya Ronal Surya
Published: September 2024

Coronary heart disease is still the leading cause of death globally. The purpose of this study was to analyze the effect of spirituality on the self-management of coronary heart disease patients. The research design used a cross-sectional study. Samples were 145 patients who had been diagnosed with coronary heart. The research variables are spirituality and self-management. The instrument uses a questionnaire. Data analysis was performed by linear regression test. The results of the study show that the spirituality of coronary heart disease (CHD) patients on the belief in God dimension is 51% high, search for meaning is 74.5% high, mindfulness is 66.2% high and feeling of security is 59.3% high. Meanwhile, the self-management of problem recognition 52.4% good, outcome of expectancy 62.8% good, planning 50.3% good and decision making 94.5% good. The results of the linear regression analysis test showed that belief in God had an effect on problem recognition (p-value 0.004), outcome expectancy
 (p-value<0.001) and planning (p-value<0.001). While search for meaning, mindfulness and feeling of security do not affect all indicators of self-management.